Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo-Reference-Cited by-同舟云学术

Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo

Published:2007-08-01 Issue:8 Volume:117 Page:2241-2249
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Schwarzwaelder Kerstin,Howe Steven J.,Schmidt Manfred,Brugman Martijn H.,Deichmann Annette,Glimm Hanno,Schmidt Sonja,Prinz Claudia,Wissler Manuela,King Douglas J.S.,Zhang Fang,Parsley Kathryn L.,Gilmour Kimberly C.,Sinclair Joanna,Bayford Jinhua,Peraj Rachel,Pike-Overzet Karin,Staal Frank J.T.,de Ridder Dick,Kinnon Christine,Abel Ulrich,Wagemaker Gerard,Gaspar H. Bobby,Thrasher Adrian J.,von Kalle Christof

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference31 articles.

1. Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease

2. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

3. Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy

4. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

5. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of CAR-T treatment toward the potential risk of second malignancies;Frontiers in Immunology;2024-05-02

2. Advanced Therapy Medicinal Products: Clinical, Non-clinical, and Quality Considerations;Pharmaceutical Biotechnology;2024

3. Vector-Mediated Genotoxicity and Mutagenicity in Hematopoietic Stem Cell Gene Therapy;Comprehensive Hematology and Stem Cell Research;2024

4. Retrovirale Vektoren – Effiziente Gentaxis für unterschiedliche Gentherapien;Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft;2023-12-30

5. Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing;Molecular Therapy - Methods & Clinical Development;2023-03